Revolutionising drug discovery

Renowned futurist Ray Kurzweil has predicted a seismic shift in the balance of power between man and machine: a momentous occasion he calls “the singularity”. This prophecy foresees a time, likely to occur around 2045, when computers will surpass human intelligence, ushering in an era of unfathomable technological advancement.

The potential of AI in drug discovery

The impact of this impending technological singularity cannot be overstated: it has the potential to upend society’s very foundations and fundamentally alter our perception of what it means to be human.

The key to reaching this pinnacle of technological progress lies in the creation of an artificial intelligence (AI) that surpasses even the most exceptional human intellects. Such a feat would unleash a torrent of novel ideas and innovations, paving the way for the emergence of unimaginable technological marvels that could transform our world beyond recognition.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Poolbeg Pharma

More articles like this

AI-powered drug discovery is changing the future of medicine

The pharmaceutical industry is being revolutionised by AI, transforming drug discovery with faster research and innovative treatments. Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, leveraging a novel clinical model for faster product development.

The Medicine of Tomorrow

Discover how groundbreaking research is revolutionising disease treatment at Monash Institute of Pharmaceutical Sciences. AI, biology, and data converge for life-changing advancements.

Hookipa Pharma advancing bold acquisition plans with Poolbeg Pharma

US-based biopharmaceutical innovator Hookipa Pharma is advancing non-binding discussions to acquire London-based Poolbeg Pharma in an all-share deal. This transformative proposal could reshape the clinical-stage biopharmaceutical landscape, creating a Nasdaq-listed powerhouse focused on next-generation immunotherapies for